CTLA4 and neoplasm: Immune checkpoint inhibitors (ICIs), such as PD-1 and CTLA-4 inhibitors, restore T cell function by alleviating the immunosuppressive effects of the tumor microenvironment, enabling T cells to effectively attack tumor cells.